<DOC>
	<DOC>NCT01907048</DOC>
	<brief_summary>This cross-sectional epidemiologic study will measure physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.</brief_summary>
	<brief_title>Patient and Physician Knowledge of Key Safety Messages</brief_title>
	<detailed_description />
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Inclusion criteria: Prescription of rivaroxaban in the past 6 months for adult patients for the Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT. Patient eligibility: Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and above; able to understand and complete the consent form and patient questionnaire.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Survey</keyword>
	<keyword>Effectiveness of risk minimization measures</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Anticoagulants</keyword>
</DOC>